Cellastra, a Pioneer leading the Path in Stem Cell Engineering & Genomics towards Regenerative Medicine and Therapeutics.

Cellastra Inc. is a Stem Cells Therapeutics & Pharmacogenomics company that aims to develop, patent and commercialize innovative, cutting-edge technologies for developing human embryonic stem cells (hESCs) based therapeutics and research tools. 

Cellastra’s Unique Assets

* A unique, large, growing inventory of the highest quality pluripotent human embryonic stem cell lines being developed by Cellastra co-founder Dr. Outi Hovatta, MD, PhD, Professor, Karolinska Institute, Stockholm, Sweden. CellastraHSC^TM stem cell lines are mainly intended for commercial companies under individually negotiated licenses for developmental and research applications, including drug discovery in regenerative medicine, toxicology, development of anti-cancer agents, development of animal models transplanted with human stem cells. CellastraHSC^TM  lines have applications in developing treatments for Neurodegenerative disorders like Parkinson’s disease, Diabetes, Leukemia, Tissue Regeneration  and Cancer.

* Cellastra’s comprehensive Genetic Portfolio CellastraGenie^TM as the fundamental tool in Pharmacogenomics allowing for rapid data analysis and facilitating safe, effective design of clinical trials, focusing on Personalized Medicine. CellastraGenie^TM will provide information required for FDA approval, establish clonal population of stem cells for transplantations, develop Biomarkers to establish pluripotent versus differentiated state of cells. This information allows for Managed, Regulated use of pluripotent cells.

* Integrated Analysis and Genomic Database Development of the complex stem cells development and differentiation molecular processes.